Project Details
Description
Attenuated strains of Salmonella have been used as carriers of heterologous
antigens for human and animal vaccination. in mice, S. typhimurium normally
infects macrophages in the Peyer's patches of the gut and also cells of the
liver and the spleen. We will compare the immune response of mice orally-
inoculated with S. typhimurium which expresses one of two model antigens:
(l) Simian immunodeficiency virus gag protein (SIV gag) and (2) the B
subunits of Shiga-like toxin type l (SLT-l) and SLT-ll from
Enterohemorragic E. coli. One of these strains, designed to enhance a
cellular immune response to an antigen, will deliver DNA encoding the IL-1
2 cytokine and the SIV gag protein directly to macrophages which will then
appropriately transcribe, translate, and process these proteins. To do
this, the Salmonella strain will contain two sets of prokaryotic genes
under a tightly regulated promoter that after phagocytosis will 1) liberate
the bacteria from the phagosome into the cytoplasm of a macrophage, and
then 2) lyse the bacterium thereby releasing a prokaryotic/eukaryotic
shuttle vector carrying cytokine and viral DNA into the cytoplasm of the
macrophage. Those macrophages infected with the Salmonella carrier strains
will process the antigen and co-express specific cytokines thus resulting
in a targeted and specific enhanced immune response. One of the other
strains, designed to augment a mucosal immunity, will co-express IL-5, a
cytokine that augments slgA production, together with the SLT protective
antigens. finally, we will use the Salmonella vaccine system to evaluate
the type of T cell response generated to a heterologous antigen that is
delivered via a vaccine strain directly to the cytoplasm of an antigen
presenting cell. The results from these studies have direct application to
the production of effective vaccines that can specifically modulate the
immune system to develop a protective response against intracellular and
extracellular pathogens.
antigens for human and animal vaccination. in mice, S. typhimurium normally
infects macrophages in the Peyer's patches of the gut and also cells of the
liver and the spleen. We will compare the immune response of mice orally-
inoculated with S. typhimurium which expresses one of two model antigens:
(l) Simian immunodeficiency virus gag protein (SIV gag) and (2) the B
subunits of Shiga-like toxin type l (SLT-l) and SLT-ll from
Enterohemorragic E. coli. One of these strains, designed to enhance a
cellular immune response to an antigen, will deliver DNA encoding the IL-1
2 cytokine and the SIV gag protein directly to macrophages which will then
appropriately transcribe, translate, and process these proteins. To do
this, the Salmonella strain will contain two sets of prokaryotic genes
under a tightly regulated promoter that after phagocytosis will 1) liberate
the bacteria from the phagosome into the cytoplasm of a macrophage, and
then 2) lyse the bacterium thereby releasing a prokaryotic/eukaryotic
shuttle vector carrying cytokine and viral DNA into the cytoplasm of the
macrophage. Those macrophages infected with the Salmonella carrier strains
will process the antigen and co-express specific cytokines thus resulting
in a targeted and specific enhanced immune response. One of the other
strains, designed to augment a mucosal immunity, will co-express IL-5, a
cytokine that augments slgA production, together with the SLT protective
antigens. finally, we will use the Salmonella vaccine system to evaluate
the type of T cell response generated to a heterologous antigen that is
delivered via a vaccine strain directly to the cytoplasm of an antigen
presenting cell. The results from these studies have direct application to
the production of effective vaccines that can specifically modulate the
immune system to develop a protective response against intracellular and
extracellular pathogens.
Status | Finished |
---|---|
Effective start/end date | 9/30/94 → 5/31/06 |
Funding
- National Institutes of Health: $138,279.00
- National Institutes of Health: $339,750.00
- National Institutes of Health: $339,750.00
- National Institutes of Health: $133,087.00
- National Institutes of Health: $339,750.00
- National Institutes of Health: $339,750.00
- National Institutes of Health: $339,750.00
ASJC
- Medicine(all)
- Immunology and Microbiology(all)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.